Is G a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Genpact (G) rests on Advanced Technology Solutions mix shift: ATS reached roughly ~$363 million in Q2 2026, up more than ~24% year over year, and is guided to grow at least ~25% for the full year. The bear case rests on the central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. Analysts covering it publish targets from $39.00 to $58.00 against a $44.28 share price on November 16, 2026, so even the professionals disagree by 41% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
G key stats
At $44.28 on November 16, 2026, Genpact (G) has a market cap of $7.4B, a P/E of 12.9 on trailing earnings (9.8 on forward earnings) and a dividend yield of 1.69%. It next reports earnings around February 4, 2027 (estimated).
- Market cap
- $7.4B
- P/E (trailing)
- 12.9
- P/E (forward)
- 9.8
- EPS (trailing 12 months)
- $3.43
- Price to book
- 2.7
- Dividend yield
- 1.69%
- Beta
- 0.54
- Next earnings
- around February 4, 2027 (estimated)
Market cap, P/E and yield are measured at the $44.28 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Genpact (G)?
The last two weeks for Genpact, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- G closed at $44.28 on November 16, 2026, up 4.1% over the past five trading days (from $42.55).
- Genpact next reports quarterly results around February 4, 2027 (estimated).
- On November 12, 2026, Genpact filed an 8-K with the SEC reporting the results of a shareholder vote (Item 5.07). Read the 8-K on sec.gov
- On November 6, 2026, Genpact filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, Genpact filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 9, 2026, Citigroup raised its target to $44.00 from $36.00 (Neutral).
- On November 6, 2026, Susquehanna raised its target to $42.00 from $40.00 (Neutral).
- On November 6, 2026, Needham raised its target to $55.00 from $45.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Genpact Limited was spun out of GE's Indian back-office operations in 2005 and has spent two decades running processes that its clients would rather not run themselves: accounts payable, order-to-cash, procurement, claims handling, anti-money-laundering alert review, supply-chain planning and customer service. Revenue comes from long-duration contracts with roughly 800 clients concentrated in banking and capital markets, insurance, consumer goods, life sciences and high-tech manufacturing, delivered by a workforce of around 141,000 people spread across India, the Philippines, Eastern Europe and Latin America. Trailing twelve-month revenue is about ~$5.25 billion, and the business is structurally profitable, with gross margin near ~36.5% and a consistent record of converting earnings into free cash flow, dividends and buybacks. The investment picture is a race between two lines on the same income statement. Management has reclassified the company as an "agentic and advanced technology solutions" firm, and the Advanced Technology Solutions segment grew more than ~24% year over year in Q2 2026 to roughly ~$363 million, with full-year growth guided at ~25% or better. Against that, the legacy headcount-linked work grows slowly and faces the obvious threat: if an AI agent can clear an invoice exception, the client no longer needs to pay for the seat that used to. Total revenue growth of about ~7% is the net of those two forces. The market has settled on a valuation that assumes the erosion wins, which is why the stock closed at $37.06 on October 16, 2026, with a market capitalisation of roughly ~$6.2 billion, despite growing earnings at a low-teens rate. The shares have recovered ~23% over the past three months but remain ~19% lower year to date and ~5% lower over one year, inside a 52-week range of ~$26.85 to ~$48.64. In October the company launched an agentic accounts receivable suite and declared its next quarterly dividend, and third-quarter results are due November 5, 2026, with consensus EPS near ~$1.04 on ~$1.38 billion of revenue.
The bull case: what would have to be true for $58.00
The most optimistic published target on G is $58.00, +31.0% from the $44.28 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Advanced Technology Solutions mix shift.
ATS reached roughly ~$363 million in Q2 2026, up more than ~24% year over year, and is guided to grow at least ~25% for the full year. Because it carries higher margins than seat-based operations work, every point of mix shift lifts blended profitability. The segment is still a minority of total revenue, so it has to compound for several more years before it drives the consolidated growth rate.
2. Agent-shaped repackaging of existing service lines.
Rather than positioning AI as a separate product, Genpact is rebuilding known offerings into agentic form, such as accounts payable delivered as an agent and a Transaction Monitoring Analyst that works AML alerts with human review and an audit trail. This matters commercially because it lets the company charge for outcomes on processes it already owns, inside compliance-heavy workflows where the client cannot simply hand the job to a general-purpose model. Q2 2026 produced record quarterly bookings and six large deals. The October 14, 2026 launch of an agentic accounts receivable suite, aimed at cash flow and working capital, extends the same approach to order-to-cash.
3. Operating leverage and capital return.
Q2 2026 gross margin expanded about 60 basis points to ~36.5% while adjusted EPS rose ~13.6% to roughly ~$1.00, so earnings are growing meaningfully faster than the ~7% top line. The board raised the quarterly dividend about ~10% to ~$0.1875 per share, an annualised ~$0.75, and repurchased roughly ~$146 million of stock between October 2025 and February 2026, close to ~2% of shares outstanding. On October 15, 2026 the board declared the next quarterly dividend, and at ~8x forward earnings buybacks do real work on per-share figures. Trailing free cash flow is about ~$479 million, near 8% of the market value.
4. Regulated-industry domain depth.
Banking, insurance and life sciences account for a large share of revenue, and those clients need explainability, auditability and named accountability before an autonomous process reaches production. That requirement slows adoption, which is a headwind on growth and a moat on retention at the same time. It is the main reason a services firm can charge for AI-mediated work that a client could in principle build in-house.
The bear case: what would have to be true for $39.00
The most pessimistic published target is $39.00, -11.9% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Genpact is worth if the risks below bite instead of the drivers above.
The central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. A second risk is client concentration and long sales cycles, where a handful of large renewals repriced downward can move a quarter. Currency is a live factor because costs sit largely in Indian rupees and Philippine pesos while revenue is billed mostly in dollars, so moves cut both ways on margin. Immigration and offshoring policy, along with any US tax or visa change targeting outsourced services, is a recurring political exposure for the whole India-delivery cohort. Finally, the cheap multiple is itself information: the market is pricing a business it believes is being disintermediated, and a low valuation offers no protection if that view turns out to be correct.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding G already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on G
11 analysts cover G, with an average target of $46.73 (+5.5% against $44.28) and a split of 5 buy, 7 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the G forecast and price target page.
How is G valued?
Market cap, P/E and dividend yield at today's price are in the G key stats above. The business figures below come from Genpact's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$5.25B; Q2 2026 ~$1.34B, up ~7.1% year over year
- Q2 2026 adjusted EPS: ~$1.00 vs ~$0.97 consensus, up ~13.6%
- Margins (TTM): Gross ~36.5%, operating ~15.0%, net ~11.1%
- Net income (TTM): ~$583M; free cash flow ~$479M
- Annualised dividend: ~$0.75 per share (~2.0% yield)
As of October 2026: Genpact trades at roughly ~1.2x trailing revenue and about 8x forward earnings as of October 2026, near the bottom of the IT and business-services group, even after a ~23% three-month rebound. That gap exists because investors are discounting the durability of headcount-linked outsourcing revenue in an AI environment, not because current results are weak: Genpact has beaten EPS estimates in each of the last four quarters, and third-quarter results on November 5, 2026 carry a consensus near ~$1.04 of EPS, in line with company guidance of roughly ~$1.04 to ~$1.05. The valuation debate is about terminal demand rather than near-term execution.
How do you decide if G is a buy?
Whether G is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold G indirectly through an index or sector ETF before adding more.
What would change your mind on G
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Advanced Technology Solutions mix shift stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the G stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about G against your real portfolio and see your actual exposure before deciding.
Your questions about Genpact
Ask Walnut's AI anything about G and see how it fits what you own.
FAQ
Is G a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Advanced Technology Solutions mix shift, with revenue (ttm) at ~$5.25B; Q2 2026 ~$1.34B, up ~7.1% year over year. The bear case rests on the central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. Analysts covering it are spread from $39.00 to $58.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell G?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $39.00, -11.9% from the $44.28 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for G?
+
Advanced Technology Solutions mix shift. ATS reached roughly ~$363 million in Q2 2026, up more than ~24% year over year, and is guided to grow at least ~25% for the full year. The most optimistic analyst target on G is $58.00, +31.0% from the $44.28 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for G?
+
The central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. A second risk is client concentration and long sales cycles, where a handful of large renewals repriced downward can move a quarter. Currency is a live factor because costs sit largely in Indian rupees and Philippine pesos while revenue is billed mostly in dollars, so moves cut both ways on margin. Immigration and offshoring policy, along with any US tax or visa change targeting outsourced services, is a recurring political exposure for the whole India-delivery cohort. Finally, the cheap multiple is itself information: the market is pricing a business it believes is being disintermediated, and a low valuation offers no protection if that view turns out to be correct. The most pessimistic published target is $39.00, -11.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Genpact do?
+
Business-process and analytics services firm spun out of GE in 2005, running finance, supply-chain and risk operations and repositioning around agentic AI.
What would have to change for G to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Advanced Technology Solutions mix shift) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Genpact actually do?
+
It runs business processes for large companies under multi-year contracts: accounts payable and receivable, procurement, financial planning, insurance claims, anti-money-laundering alert review, supply-chain planning and customer service. It also provides data, analytics and AI implementation work. Clients outsource these functions to cut cost and to access specialist process expertise they do not want to build internally.
How do you invest in G?
+
Genpact Limited trades on the New York Stock Exchange under the ticker G, so it is accessible through any standard US brokerage account that supports NYSE-listed shares, including via fractional shares at brokers that offer them. Some investors hold it inside a broader IT-services or thematic grouping alongside peers rather than as a standalone position.
Is Genpact profitable?
+
Yes. Q2 2026 produced net revenue of roughly ~$1.34 billion with gross margin near ~36.5% and adjusted diluted EPS of about ~$1.00, up ~13.6% year over year. The company has been consistently profitable and cash-generative for years, which is what funds the dividend and the buyback programme. Over the trailing twelve months net income was about ~$583 million on ~$5.25 billion of revenue.
Walnut is informational, not investment advice, and gives no verdict on G. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.